Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Pilar de la Morena Barrio"'
Autor:
Esmeralda García-Torralba, Esther Navarro Manzano, Gines Luengo-Gil, Pilar De la Morena Barrio, Asunción Chaves Benito, Miguel Pérez-Ramos, Beatriz Álvarez-Abril, Alejandra Ivars Rubio, Elisa García-Garre, Francisco Ayala de la Peña, Elena García-Martínez
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundUp to 30% of breast cancer (BC) patients treated with neoadjuvant chemotherapy (NCT) will relapse. Our objective was to analyze the predictive capacity of several markers associated with immune response and cell proliferation combined with
Externí odkaz:
https://doaj.org/article/45fb4d2560e8406c9b0a23f5e2b11e43
Autor:
Silvia Antolín Novoa, Santiago Escrivá-de-Romaní, Pablo Tolosa Ortega, Lucía Oliva Fernández, Rafael López López, Ana López González, Pilar de la Morena Barrio, Isabel Echavarria Díaz-Guardamino, José Enrique Alés Martinez, Zita Garate, Lucia González-Cortijo
Publikováno v:
Cancer Treatment and Research Communications, Vol 37, Iss , Pp 100772- (2023)
Introduction: Trastuzumab emtansine (T-DM1) significantly improves invasive disease-free survival and reduces the risk of recurrence in patients with HER2-positive early breast cancer (EBC) with residual disease (RD). The KARMA study aimed to describ
Externí odkaz:
https://doaj.org/article/9fdeb598f4324f0391f50f42c636b7e1
Autor:
Esmeralda Garcia-Torralba, Beatriz Álvarez-Abril, Carlos Bravo-Pérez, Esther Navarro Manzano, Pilar de la Morena Barrio, Alejandra Ivars Rubio, Elisa García-Garre, Gema Marín Zafra, Francisco Ayala de la Peña, Elena García-Martínez
Publikováno v:
Cancer Research. 82:P4-07
Introduction and objectives Up to 30% of early breast cancer (BC) patients treated with neoadjuvant chemotherapy will have systemic relapse during the follow-up. The integration of clinical, analytical and molecular parameters associated to tumor bio
Autor:
Esmeralda Garcia-Torralba, Beatriz Álvarez-Abril, Carlos Bravo-Pérez, Esther Navarro Manzano, Pilar de la Morena Barrio, Alejandra Ivars Rubio, Elisa García-Garre, Gema Marín Zafra, Francisco Ayala de la Peña, Elena García-Martínez
Publikováno v:
Cancer Research. 82:P4-07
Introduction. There are still 30-40% of patients with early breast cancer (BC) that relapse after neoadjuvant chemotherapy (NAC). New prognostic biomarkers are needed. Current evidence shows that both markers of antitumor local and systemic immune re
Autor:
Esmeralda García-Torralba, Miguel Pérez Ramos, Alejandra Ivars Rubio, Esther Navarro-Manzano, Noel Blaya Boluda, Pilar de la Morena Barrio, Elisa García-Garre, Francisco Martínez Díaz, Asunción Chaves-Benito, Elena García-Martínez, Francisco Ayala de la Peña
Publikováno v:
Cancers; Volume 15; Issue 10; Pages: 2846
Luminal breast cancer (BC) is associated with less immune activation, and the significance of stromal lymphocytic infiltration (sTIL) is more uncertain than in other BC subtypes. The aim of this study was to investigate the predictive and prognostic
Autor:
Elena Garcia Martinez, Alberto Carmona-Bayonas, Beatriz Alvarez-Abril, Francisco Ayala de la Peña, Alejandra Ivars Rubio, Gema Marin Zafra, Esmeralda García-Torralba, Pilar de la Morena Barrio, Elisa García Garre
Publikováno v:
Cancer Research. 81:PS6-45
Introduction and objectives: Tumor infiltrating lymphocytes (TILs) and neutrophil-to-lymphocyte ratio (NLR) play a prognostic role in early stage breast cancer (BC). There is no evidence about the combined effect of both factors. Our objective was to
Autor:
Maria Esperanza Guirao Garcia, Esmeralda García-Torralba, Beatriz Alvarez Abril, Francisco Ayala de la Peña, Alejandra Ivars Rubio, Pilar de la Morena Barrio, Elena Garcia Martinez, Esther Navarro Manzano, Elisa García Garre, Gema Marin Zafra
Publikováno v:
Cancer Research. 81:PS6-54
Introduction and objectives Pathologic complete response (pCR, ypT0/Tis ypN0) after neoadjuvant chemotherapy (nCT) in early breast cancer (BC) is associated with higher survival rate. Controversy about the prognostic significance of low-volume or mic
Autor:
Coralia Bueno-Muiño, Isabel Echavarria, Sara López-Tarruella, Roche-Molina Marta, María del Monte-Millán, Tatiana Massarrah, Yolanda Jerez Gilarranz, Blanca Herrero, Salvador Gámez, Iván Márquez-Rodas, María Cebollero-Presmanes, Nevado Santos Manuel, Pilar de la Morena Barrio, Francisco Ayala de la Peña, José Ángel García-Sáenz, Fernando Moreno Antón, Álvaro Rodríguez Lescure, Teresa Quintanar, Diego Malón-Giménez, Laura Rodriguez-Lajusticia, Ana Isabel Ballesteros García, Dulce Bañón Torres, Lucía Villarejo, Nerea Lobato, Ainhoa Arias, Inmaculada Ocaña, Enrique Álvarez, Laia Paré, Mercedes Marín-Aguilera, Patricia Galván, Fara Brasó-Maristany, Ana Vivancos, Patricia Villagrasa, Joel S Parker, Charles M. Perou, Aleix Prat, Miguel Martín
Publikováno v:
Cancer Research. 83:P6-01
Background: HER2DX (Prat et al. EBiomedicine 2022) is a 27-gene prognostic (risk-score) and predictive (pathological complete response [pCR]-score) assay in early-stage HER2+ breast cancer based on clinical data and the expression of 4 gene signature
Autor:
Francisco Ayala, Asunción Chaves, Gema Marín, Pilar de la Morena Barrio, Francisco Pastor, Manuel Sánchez, Alejandra Ivars, Esmeralda García-Torralba, Elena Garcia, Beatriz Alvarez-Abril
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f705d8b5d885281c7ea483939d39e641
https://doi.org/10.26226/morressier.5fa3ee5d55b1fd4cc4dd93fd
https://doi.org/10.26226/morressier.5fa3ee5d55b1fd4cc4dd93fd
Autor:
Alejandra Ivars Rubio, Maria Piedad Fernandez Perez, Esmeralda García-Torralba, Elena García-Martínez, Esther Navarro Manzano, Asunción Chaves Benito, Raul Teruel Montoya, Francisco Martínez Díaz, Francisco Ayala de la Peña, Pilar de la Morena Barrio
Background: Endocrine resistance is a major cause of therapeutic failure in metastatic breast cancer (MBC). The information provided by DNA sequencing of plasma cell free DNA (cfDNA) and by the analysis of circulating tumor cells (CTC) may be useful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3b94cf28a2c76da79cd5f0067642e8c
https://doi.org/10.21203/rs.3.rs-57674/v1
https://doi.org/10.21203/rs.3.rs-57674/v1